Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Lung Non-Small Cell Carcinoma: early-phase trial registry
9 of 31 indexed Recurrent Lung Non-Small Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #495 of 28,707 conditions by registered trial count.
31 US clinical trials · 9 currently recruiting · #495 of 28,707 conditions by registered trial count
Recurrent Lung Non-Small Cell Carcinoma: 31 US clinical trials tracked, 9 recruiting.
Recurrent Lung Non-Small Cell Carcinoma is the subject of 31 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 9 of these trials.
Enrollment posture brief
Registry condition recurrent-lung-non-small-cell-carcinoma
OPEN 9 | RECR 29% | LATE 2 | EARLY 28 | RANK #495 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Fallopian Tube Cancer (29% recruiting · 93 trials)
Recurrent Lung Non-Small Cell Carcinoma lists 9 open slots (29% of 31 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Lung Non-Small Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Lung Non-Small Cell Carcinoma is recruiting below its size-band peers.
9 of 31 indexed trials (29%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Lung Non-Small Cell Carcinoma research.
National Cancer Institute (NCI) accounts for 9 of 31 trials (29%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Lung Non-Small Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 51 among the 31 trials that report a genuine target (sentinel values excluded). 21 of those (67.7%) plan for fewer than 100 participants.
-
Recurrent Lung Non-Small Cell Carcinoma research is mostly interventional.
31 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
31 total, page 1 of 1
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT06616584
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
University of Washington
NCT04151940
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT05642572
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT06031688
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
National Cancer Institute (NCI)
NCT03191149
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Dwight Owen
NCT05234307
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
University of Washington
NCT05570825
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Dwight Owen
NCT06616623
MOv19-BBz CAR T Cells in FRa+ Cancers
University of Pennsylvania
NCT07116057
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
NCT05633602
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04092283
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
M.D. Anderson Cancer Center
NCT03410043
Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT01629498
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03110978
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
National Cancer Institute (NCI)
NCT02496663
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT01708954
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
NCT04268550
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
NCT04533451
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT05096663
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT02642042
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03600701
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
M.D. Anderson Cancer Center
NCT03225664
Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT02503722
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03707938
NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT04505267
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04250545
All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Dwight Owen
NCT04919369
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT04837716
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
University of California, Irvine
NCT05334329
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
City of Hope Medical Center
NCT04227028
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT02535338
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 13 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Lung Non-Small Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Lung Non-Small Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Lung Non-Small Cell Carcinoma page
31 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Recurrent Lung Non-Small Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Lung Non-Small Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Lung Non-Small Cell Carcinoma condition card totals 31 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.